Radiation sickness, or acute radiation syndrome, might now be identified within hours of radiation exposure using a new finger-stick blood test developed by researchers. This condition occurs as a consequence of nuclear radiation or radioactive fallouts due to a nuclear weapon detonation or reactor accidents and can affect several sensitive organs within the body.

In an attempt to create the first-in-human approved biodosimetry assay for the estimation of absorbed ionising radiation dose, Marshleen Yadav and colleagues at The Ohio State University (Columbus, OH, USA) identified a pair of microRNA molecules in the blood that can be used to determine the degree of radiation exposure and assess whether or not toxicity has occurred. They identified one biomarker, microRNA-150, which is highly expressed in blood cells and is sensitive to radiation (its concentration in the bloodstream decrease as radiation exposure increases) and another, microRNA-23a, which is abundant in the bloodstream but remains unchanged upon radiation exposure. The investigators first identified these microRNAs in mice and then validated their findings in human patients with leukaemia who received fractionated radiotherapy.

This breakthrough diagnostic method offers a promising alternative to the standard dicentric chromosome assay, which looks for signs of DNA damage caused by radiation and can take several days to produce results. Existing peripheral blood cell-based methods such as this are labour-intensive and time-consuming. Because individuals who have been exposed to toxic amounts of radiation require urgent and aggressive treatment, and because the period immediately after exposure is the most important in terms of the identification and triaging of patients, this accelerated diagnosis from a few days to only a few hours has the potential to substantially improve individual prognosis and save lives.

In addition to the benefits of reducing this diagnostic timeframe on an individual basis, the ease and scalability of the new finger-stick test makes it an opportune tool for screening large numbers of people within a short period of time. This feature is particularly useful when considering major nuclear disasters, such as Chernobyl and Fukushima, in which entire populations might be affected and require immediate testing to assess the severity of their radiation exposure. Persistent [links](https://www.nature.com/articles/s41598-020-60999-z){#interrefs10} between the meltdown of the Fukushima Daiichi Nuclear Power Plant in 2011 and the increased incidence of thyroid cancer in children and young adults in the region, detected through a large-scale mass ultrasound thyroid screening programme put in place after the disaster, indicate the value of mass screening and monitoring for those overexposed to radiation. Moreover, a [study](https://www.sciencedirect.com/science/article/pii/S0048969720340614?via%3Dihub){#interrefs20} published in July, 2020, showed that the Fukushima disaster released not only radioactive cesium but also particles of plutonium into the atmosphere underlines the invisible dangers such incidents continue to pose to public health several years after the event.

The potential scalability of the finger-stick test is also a very important consideration in clinical oncology settings, in which large numbers of patients stand to benefit from precise, accelerated screening for radiation exposure.

"Beyond its utility in preparedness for a nuclear disaster, the assay has potential applications in radiation oncology and bone marrow transplant clinics," study author Naduparambil K Jacob explained. "There are differences in radiation sensitivity in humans and overdosing as well as under-dosing, which is of concern. Currently, at least in the field of radiation oncology, clinicians follow a one size fits all approach. Molecular assays like this will likely help in modifying the regimen during the fractionated radiation based on individuals\' physiological response."

"We have shown dose response in irradiated human leukaemia patients during marrow ablation and reconstitution after bone marrow transplant and we have done baseline comparisons in healthy humans," he continued. "However, additional pivotal validation studies following FDA-2 animal rule using non-human primates as a model is needed for potential regulatory approval."

Whatever the application, the speed and convenience of this new diagnostic tool is essential to its future uptake, as Norman Coleman (National Cancer Institute, Bethesda, MD, USA) observed: "The importance of a rapid diagnostic tool has been demonstrated in the COVID-19 management, such that a person\'s medical needs can be determined rapidly and they can be directed to either required treatment or to appropriate reassurance. For a resource-limited situation when there is more need than resources for everyone, the benefit to knowing who does not require treatment allows the available resources to be utilized most effectively and for someone who does not require a treatment to avoid it and the potential toxicity."

"Importantly, these assays are biomarkers that estimate some degree of damage to a person or an organ system," added Coleman. "Critical with biomarkers is that the result is one piece of data that helps the physician or health-care professional assess the patients\' needs. A blood test does not progress to a treatment without a professional making the determination."

For the **study reporting the new finger-stick test** see *Sci Transl Med* 2020; published online July 15. <https://stm.sciencemag.org/content/12/552/eaaw5831.full>
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